I'm too foggy to start writing letters to places right now. But here is a basic point that the CDC response sidesteps.
Checking ones assays against samples found positive by others is a scientific method for double-checking the validity of ones tests. It is not outside the realm of routine publication to include information about validation steps, even if the results call for more testing. By omitting information about these results, they deprive other scientists potentially useful information. They deprive other scientists the opportunity to decide whether the inconsistencies the CDC found need further consideration.
The Centers for Disease Control have a professional and moral obligation to assist in the control of disease. But their actions show only half-hearted attempt to do this. Some might even say this is lying by omission. But either way, they have fallen short of their charter to promote the control of disease. Their lack of full disclosure interferes with other scientists having as much information as possible from which to work. And in making excuses for doing this, the CDC has taken the lower moral ground.
The CDC had no interest in really testing those samples. They don't want the XMRV investigation to go anywhere. The question that should be asked is why haven't they also done a study that was calibrated with those samples?
Who do they think they're fooling?
The morality on display here is not the immediate question. What bothers me about that response (or lack of same) is the implication that the validity of their test assay is not a subject open to discussion. If you can't compare the work of one group with another, and ask questions about the basis, you can't do science. (Perhaps, we should ask what they have been in the business of doing for 25 years.)Well said. That lower moral ground seems to be subterranean at this point.
The morality on display here is not the immediate question. What bothers me about that response (or lack of same) is the implication that the validity of their test assay is not a subject open to discussion. If you can't compare the work of one group with another, and ask questions about the basis, you can't do science. (Perhaps, we should ask what they have been in the business of doing for 25 years.)
They deliberately inserted a statement in their paper about the lack of a panel of control subjects/specimens which, given the omission we now recognize, was deliberately misleading. They have created an assay, and now plaintively ask for someone else to provide controls which will validate their results without validating claims that some people are infected. Quite a conundrum. (Note: These people need not be CFS/ME patients, though I expect it will be easier to find infection in such. Ila Singh found a way around reliance on WPI for samples. The CDC didn't try.)
I'm glad I don't have to defend their "Test Assay Development" in front of a room full of PhDs. It could be a memorable spectacle.
Vincent Racaniello, who hasn't appeared to be that tough of a CDC critic (at least on this paper), made the point that as a peer reviewer he would have asked for the CDC to display they could detect XMRV in blood. But as the CDC said, they adhered to the study design. Arrrgh. I am continually amazed at their transparency. Who do they think they're fooling?
Who do they think they're fooling?
Hey Otis, obviously they are not fooling many of the sharp folks here, but they probably think they are fooling enough to get away with it politically? Michelle Bachmann and death panels????![]()